Q2 EPS Forecast for Neurocrine Biosciences Lifted by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for Neurocrine Biosciences in a report released on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.63 per share for the quarter, up from their prior estimate of $0.58. HC Wainwright has a "Buy" rating and a $168.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.17 EPS, FY2026 earnings at $4.19 EPS and FY2029 earnings at $13.44 EPS.

Several other equities research analysts have also recently issued reports on NBIX. UBS Group raised their target price on Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Royal Bank of Canada upped their target price on shares of Neurocrine Biosciences from $137.00 to $145.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. Morgan Stanley reiterated an "overweight" rating and set a $150.00 price target (down from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. Finally, Piper Sandler restated an "overweight" rating and issued a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $2.21 during midday trading on Thursday, reaching $118.22. 583,891 shares of the stock were exchanged, compared to its average volume of 1,115,785. The stock has a market capitalization of $11.70 billion, a P/E ratio of 35.93, a PEG ratio of 0.77 and a beta of 0.26. The company has a 50 day simple moving average of $106.36 and a 200 day simple moving average of $121.93. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The firm had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. During the same quarter in the previous year, the business posted $1.20 earnings per share. Neurocrine Biosciences's revenue for the quarter was up 11.1% on a year-over-year basis.

Institutional Trading of Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the business. Golden State Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Huntington National Bank increased its stake in Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group raised its holdings in Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock worth $32,000 after purchasing an additional 115 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Neurocrine Biosciences during the 1st quarter worth approximately $34,000. Finally, GeoWealth Management LLC lifted its position in shares of Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after buying an additional 102 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now directly owns 521,618 shares of the company's stock, valued at approximately $60,867,604.42. The trade was a 1.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter sold 30,000 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the transaction, the director now directly owns 37,491 shares in the company, valued at $4,131,508.20. This trade represents a 44.45% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,953 shares of company stock worth $4,467,990. Company insiders own 4.80% of the company's stock.

Neurocrine Biosciences declared that its board has approved a share buyback plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.